Advertisement

Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases

Abstract

The introduction of targeted agents did not totally resolve the approach to the treatment of metastatic renal cell carcinoma (mRCC) because complete response is rarely achieved. Recent findings seem to indicate that metastasectomy may improve survival. The RESORT study was designed to evaluate the additional clinical benefit of metastasectomy followed by sorafenib in a population of mRCC patients.
With the aim of evaluating time to recurrence, 132 patients with mRCC who underwent radical resection of metastases at the time of recurrence after nephrectomy will be randomized to receive either sorafenib or best supportive care. Targeted treatment will be administered for up to 52 weeks or discontinued in the case of disease recurrence or unacceptable toxicity. Patients will be followed for a period of 36 months.

Tumori 2014; 100(1): e28 - e30

Article Type: EDITORIAL

DOI:10.1700/1430.15834

Authors

Giuseppe Procopio, Elena Verzoni, Pamela Biondani, Paolo Grassi, Isabella Testa, Enrico Garanzini, Filippo de Braud

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Procopio, Giuseppe [PubMed] [Google Scholar]
    Department of Medical Oncology, Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
  • Verzoni, Elena [PubMed] [Google Scholar]
    Department of Medical Oncology, Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
  • Biondani, Pamela [PubMed] [Google Scholar]
    Department of Medical Oncology, Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
  • Grassi, Paolo [PubMed] [Google Scholar]
    Department of Medical Oncology, Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
  • Testa, Isabella [PubMed] [Google Scholar]
    Department of Medical Oncology, Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
  • Garanzini, Enrico [PubMed] [Google Scholar]
    Department of Medical Oncology, Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
  • de Braud, Filippo [PubMed] [Google Scholar]
    Department of Medical Oncology, Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.